|
MedChemExpress
selective hdac2 inhibitor Selective Hdac2 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/hdac2/HDAC2+Antibody/pm41192741-57-20-23 Average 95 stars, based on 1 article reviews
selective hdac2 inhibitor - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Novus Biologicals
hdac2 Hdac2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/hdac2/Histone+Deacetylase+2%2FHDAC2+Antibody/pm26949823-41-23-26 Average 90 stars, based on 1 article reviews
hdac2 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
hdac2 Hdac2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/hdac2/HDAC2+Rabbit+mAb/pm39707321-119-58-79 Average 95 stars, based on 1 article reviews
hdac2 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Proteintech
anti hdac2 Anti Hdac2, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/hdac2/HDAC2+Antibody/pmc12130724-77-39-41 Average 95 stars, based on 1 article reviews
anti hdac2 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
sihdac2 Sihdac2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/hdac2/HDAC2+siRNA/pmc05823910-409-22-23 Average 93 stars, based on 1 article reviews
sihdac2 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
antibody against hdac2 ![]() Antibody Against Hdac2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/hdac2/HDAC2+Antibody/10__1017_slash_s1461145714000248-82-18-21 Average 96 stars, based on 1 article reviews
antibody against hdac2 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Fortis Life Sciences
anti chd7 ![]() Anti Chd7, supplied by Fortis Life Sciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/hdac2/HDAC2+Antibody/pmc05623824-78-6-10 Average 93 stars, based on 1 article reviews
anti chd7 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
OriGene
pcmv sport6 chd4 ![]() Pcmv Sport6 Chd4, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/hdac2/Hdac2+(NM_008229)+Mouse+Tagged+ORF+Clone/pmc07968368-100-67-66 Average 90 stars, based on 1 article reviews
pcmv sport6 chd4 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
hdac2 shrna m lentiviral particles ![]() Hdac2 Shrna M Lentiviral Particles, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/hdac2/HDAC2+shRNA+(m)+Lentiviral+Particles/pmc06608318-386-0-7 Average 88 stars, based on 1 article reviews
hdac2 shrna m lentiviral particles - by Bioz Stars,
2026-11
88/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
anti hdac2 antibody ![]() Anti Hdac2 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/hdac2/HDAC2+Antibody/pmc06689058-268-4-6 Average 94 stars, based on 1 article reviews
anti hdac2 antibody - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
Image Search Results
Journal: The International Journal of Neuropsychopharmacology
Article Title: Repeated treatment with electroconvulsive seizures induces HDAC2 expression and down-regulation of NMDA receptor-related genes through histone deacetylation in the rat frontal cortex
doi: 10.1017/s1461145714000248
Figure Lengend Snippet: Fig. 1. Repeated ECS treatments induce HDAC2 mRNA and protein expression in the rat frontal cortex. (a) mRNA expression of class I Hdacs (Hdac1, Hdac2, and Hdac3) was analyzed with qRT-PCR, and values relative to the sham control (S) are presented. The Hdac2 mRNA level was significantly increased in the rat frontal cortex 24 h after repeated ECS treatments for 5 d (E5X) and for 10 d (E10X). (b) Representative immunoblots and quantified immunoblot values of class I HDACs (HDAC1, HDAC2, and HDAC3) from the rat frontal cortex are presented. HDAC2 immunoreactivity was increased in the rat frontal cortex by E10X. The immunoreactivity value was quantified using a densitometric analysis of band intensity and is presented as relative optical density (OD) vs. the control. Values are presented as means±S.E. *, p<0.05 (n=4–8 for each treatment group).
Article Snippet: The sections were blocked for 1 h with 3% BSA in TBST and then incubated with a specific
Techniques: Expressing, Quantitative RT-PCR, Control, Western Blot
Journal: The International Journal of Neuropsychopharmacology
Article Title: Repeated treatment with electroconvulsive seizures induces HDAC2 expression and down-regulation of NMDA receptor-related genes through histone deacetylation in the rat frontal cortex
doi: 10.1017/s1461145714000248
Figure Lengend Snippet: Fig. 2. Increased immunostaining for HDAC2 co-localized with immunofluorescence of Neu-N in the rat frontal cortex after repeated ECS treatments. (a) Representative microscopic images taken from sections stained for HDAC2 in the rat prefrontal cortex (Fr) (Paxinos and Watson, 1998). All captured images were obtained 24 h after the last of 10 daily ECS treatments (E10X). (b) The number of positive cells for HDAC2 was counted and was found to be increased in prefrontal (Fr), cingulate (Cg), insular (AI), and orbital (LO and VLO) cortical regions (Paxinos and Watson, 1998) after E10X. Values are presented as means±S.E. *, p<0.05 (n=4 for each treatment group). (c) Immunofluorescence of HDAC2 was co-localized with that of Neu-N (red) and DAPI (blue) in the rat prefrontal cortex (Fr) (Paxinos and Watson, 1998). Magnification bar=100 (a) and 20 μm (c).
Article Snippet: The sections were blocked for 1 h with 3% BSA in TBST and then incubated with a specific
Techniques: Immunostaining, Staining
Journal: Molecular Oncology
Article Title: Genotranscriptomic meta‐analysis of the CHD family chromatin remodelers in human cancers – initial evidence of an oncogenic role for CHD 7
doi: 10.1002/1878-0261.12104
Figure Lengend Snippet: Frequency (%) of CHD genetic alterations and expression levels in 960 TCGA breast cancers
Article Snippet: Antibodies used in the study included
Techniques: Expressing, Mutagenesis
Journal: Respiratory Research
Article Title: Combined genomic and proteomic approaches reveal DNA binding sites and interaction partners of TBX2 in the developing lung
doi: 10.1186/s12931-021-01679-y
Figure Lengend Snippet: Scheme of the molecular interactions of TBX2 in repression of target genes in the pulmonary mesenchyme. Grey discs represent nucleosomes. DNA is displayed as black line. Dotted line indicates unknown length of DNA fragment and possible long distance. Circles for proteins do not represent the real size. TBX2 binds in concert with HMGB2 and PBX1 to specific DNA sites in enhancer regions. Binding to PBX1 is probably indirect via unknown proteins, binding to HMGB2 is direct and may aid in chromatin bending and bringing enhancer regions to the proximity of transcription start sites. TBX2/DNMT1 binding may induce DNA methylation to repress gene expression. TBX2 and CBX3 directly bind and both associate with the NuRD complex for chromatin remodeling. TBX2/MYBBP1 interaction may strengthen the association with the NuRD complex to repress target genes. TBX2 directly interacts with components of the NuRD complex, namely HDACs for chromatin deacetylation and the chromatin remodeling complex CHD4. TBX2 interaction with CBX3, HDACs and CHD4 collectively induces chromatin compaction. RBBP4/7 binds to chromatin to consolidate binding of the NuRD-complex to target gene DNA
Article Snippet: We used the following expression vectors for transfections in HEK293 cells: pcDNA3.huTBX2.HA encoding N-terminally HA-tagged full-length human TBX2; pCS2.Pbx1b encoding full-length mouse PBX1B , (gift from Heike Pöpperl, Institute for Biophysical Chemistry, Hannover Medical School, Germany); pd2EGFP-N1 (EGFP-expression vector) [ ]; pCMV6-Entry.Cbx3-Myc-DDK encoding full-length mouse CBX3 (#MR224357, OriGene, Rockville, Maryland, USA); pCMV-SPORT6.Hdac1 encoding full-length mouse HDAC1 (#4217199, Sourcebioscience, Nottingham, UK); pCMV6-Entry.Hdac2-Myc-DDK encoding full-length mouse HDAC2 (#MR226709,
Techniques: Binding Assay, DNA Methylation Assay, Expressing
Journal: Nature Communications
Article Title: MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat
doi: 10.1038/s41467-019-11568-0
Figure Lengend Snippet: HDACs epigenetically regulate the expression of lysosomal genes. a GSEA demonstrated significant activation of the lysosomal pathway in HeLa cells treated with SAHA (20 μM for 24 h). The top 20 upregulated genes are shown at the bottom of the plot. b Expression analysis of lysosomal genes after SAHA treatment (20 μM for 24 h). The box and whisker plot show normalized expression of the lysosomal mRNAs in SAHA-treated HeLa cells relative to that in DMSO-treated cells. n = 5 biologically independent samples. c Lysosomal volume was measured by FACS analysis as mean fluorescence intensity (MFI) after lysotracker staining of HeLa cells treated with SAHA (20 μM for 24 h) and compared to cells treated with DMSO, n = 9 biologically independent samples. d Lysosomal count of transmission electron microscopy images n = 20 images. e – n Activity assays for NEU1 ( n = 7 biologically independent samples), β-hexosaminidase (β-HEX) ( n = 4 biologically independent samples), α-mannosidase (α-MAN) ( n = 5 biologically independent samples), β-galactosidase (β-GAL) ( n = 5 biologically independent samples) and cathepsin A (CA) ( n = 5 biologically independent samples) in HeLa cells treated with DMSO or SAHA ( e – i ) (20 μM for 24 h), or in HeLa cells treated with DMSO or romidepsin ( j - n ) (romidepsin, Romi, 10 nM for 24 h; n = 6 biologically independent samples). o HDAC2 occupancy was analyzed using ChIP-seq datasets available at the ENCODE/Haib project. Genes shown on the left of the vertical black line are occupied by HDAC2. p = 4.65e-11, odds ratio = 4.4, Fisher’s exact test. p ChIP analysis of the promoters of NEU1 , LAMP1 , MCOLN1 , TFEB , and TFE3 using anti-HDAC2 antibody in HeLa cells treated with SAHA (20 μM for 24 h) or DMSO ( n = 3 biologically independent samples). Oligos encompassing a genomic region at +5 Kb from the TSS of NEU1 ( NEU1 INT ) were used as control for non-specic antibody binding ( n = 3 biologically independent samples); IgG control n = 3 biologically independent samples. q ChIP analysis of the promoters of NEU1 , LAMP1 , MCOLN1 , TFEB , and TFE3 and NEU1 INT using acetyl histone H3 Lys 14 antibody (Acetyl-H3K14) in HeLa cells treated with SAHA (20 μM for 24 h) or DMSO ( n = 8 biologically independent samples); IgG control n = 3 biologically independent samples. Boxes represent the mean value and bar inside the box represents median value; upper bar represents maximum of distribution; lower bar represents minimum of distribution (95% confidence level). Graphs shown in ( c – n ) and ( p , q ) are presented as mean ±SD. Statistical analysis was performed using Student t -test
Article Snippet: Membranes were immunoblotted for
Techniques: Expressing, Activation Assay, Whisker Assay, Fluorescence, Staining, Transmission Assay, Electron Microscopy, Activity Assay, ChIP-sequencing, Control, Binding Assay
Journal: Nature Communications
Article Title: MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat
doi: 10.1038/s41467-019-11568-0
Figure Lengend Snippet: MYC occupies the promoters of lysosomal genes and that of TFEB and TFE3. a Motif analysis using HDAC2-binding sites present in lysosomal genes. b Left, silencing of HDAC2 downregulated MYC protein expression in HeLa cells. Right, Coomassie stained immunoblot used as the loading control. c Quantification of MYC levels in HDAC2 silenced HeLa cells normalized to loading control ( n = 3 independent experiments). d Co-immunoprecipitation of MYC with HDAC2 from lysates obtained from HeLa cells. HDAC2 band is labeled with an asterisk. Heavy chain IgG is labeled with an arrow. e Immunoprecipitation of MYC followed by immunoblot of MYC protein. MYC band is labeled with an asterisk. Heavy chain IgG is labeled with an arrow. f Graph represents HDAC2 binding to the promoter of MYC ( n = 5 biologically independent samples) in HeLa cells treated with DMSO and SAHA (20 μM for 24 h); IgG control ( n = 3 biologically independent samples). g – i Myc binding to the promoters of ( g ) Neu1, Ctsa , ( h ) Lamp1, Mcoln1 and i Tfeb and Tfe3 was analyzed in ChIP-seq datasets performed with anti-Myc antibody in mouse group 3 medulloblastoma cells overexpressing Myc ( Trp53 –/– overexpressing Myc ). Input DNA (Inp) serves as reference. j , k Histograms represent MYC binding to the promoters of ( j ) NEU1 ( n = 3 biologically independent samples), LAMP1 ( n = 3 biologically independent samples), MCOLN1 ( n = 3 biologically independent samples), TFEB ( n = 6 biologically independent samples), TFE3 ( n = 3 biologically independent samples) and ( k ) MYC ( n = 3 biologically independent samples) in HeLa cells treated with SAHA (20 μM for 24 h) or DMSO. NEU1 INT oligos were used as negative control for non-specific antibody binding ( n = 3 biologically independent samples); IgG control ( n = 3 biologically independent samples). l Sequential ChIP experiments were performed from HeLa cells with anti-MYC antibody followed by anti-HDAC2 antibody and analyzed by RT-qPCR at the promoter region of TFEB and TFE3 ( n = 3 biologically independent samples); IgG control ( n = 3 biologically independent samples). All the graphs are presented as mean ± SD. Statistical analysis was performed using the Student t -test. * p < 0.05, ** p < 0.01, **** p < 0.0001
Article Snippet: Membranes were immunoblotted for
Techniques: Binding Assay, Expressing, Staining, Western Blot, Control, Immunoprecipitation, Labeling, ChIP-sequencing, Negative Control, Quantitative RT-PCR
Journal: Nature Communications
Article Title: MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat
doi: 10.1038/s41467-019-11568-0
Figure Lengend Snippet: HDACs epigenetically regulate autophagy. a RT-qPCR of autophagy genes in SAHA-treated (20 μM for 24 h) HeLa ( n = 5 biologically independent samples). b EGFP-LC3 expression in HeLa treated with DMSO or SAHA (20μM for 24 h) under fed or starved conditions (EBSS). Scale bar, 20 μm. c Quantification of EGFP-LC3 ( n = 12 images). d Top, representative image of anti-LC3 immunoblot of HeLa treated with DMSO (D) or SAHA (S) (20 μM for 24 h) under fed or starved conditions (EBSS) with or without Bafilomycin A1 (BAF) to assess the autophagic flux; short and long exposure. Bottom, Coomassie stained immunoblot used as loading control e Quantification of LC3II/LC3I ratio ( n = 5 independent experiments) normalized to the loading control and relative to DMSO FED values; D = DMSO, S = SAHA, starved = EBSS treatment. f HDAC2 occupancy of autophagy gene promoters analyzed using ChIP-seq datasets from the ENCODE/Haib project. Genes on the left of the vertical black line are occupied by HDAC2. p = 4.656e-08, odds ratio = 6.0, Fisher’s exact test. g ChIP analyses of the MAP1LC3B promoter using anti-HDAC2 antibody was performed in HeLa treated with SAHA (20μM for 24 h) or DMSO ( n = 6 biologically independent samples); IgG control ( n = 3 biologically independent samples). h ChIP analysis of the promoter of MAP1LC3B using acetyl histone H3 Lys 14 antibody (Acetyl-H3K14) in HeLa treated with SAHA (20 μM for 24 h) or DMSO ( n = 6 biologically independent samples); IgG control ( n = 3 biologically independent samples). i , j RT-qPCR of ( i ) Gabarapl2 , Map1lc3b and ( j ) Pik3c3 and Sqstm1 was performed after SAHA treatment (20μM for 24 h) in WT MEFs, in MEFs with CRISPR-mediated knockout of Tfeb and Tfe3 (dKO) and in MEFs dKO silenced for Mitf (dKO + shMitf) ( n ≥ 6 biologically independent samples). shC refers to cells transduced with shRNA control lentivirus. Statistical analysis was performed comparing the normalized expression of the autophagy genes in MEFs WT + shC versus dKO + shC and in MEFs WT + shC versus dKO + shMitf. Boxes represent the mean value and bar inside the box represents median value; upper bar represents maximum of distribution; lower bar represents minimum of distribution (95% confidence level). Graphs are presented as mean ± SD. Statistical analysis was performed using the Student t-test. * p < 0.05, ** p < 0.01, **** p < 0.0001
Article Snippet: Membranes were immunoblotted for
Techniques: Quantitative RT-PCR, Expressing, Western Blot, Staining, Control, ChIP-sequencing, CRISPR, Knock-Out, Transduction, shRNA
Journal: Nature Communications
Article Title: MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat
doi: 10.1038/s41467-019-11568-0
Figure Lengend Snippet: FOXH1 is an additional activator of autophagy and responds to the HDACs/MYC axis. a Motif analysis using HDAC2-binding sites for autophagy genes identified the FOXH1 motif. b RT-qPCR of autophagy genes in FOXH1-overexpressing HeLa cells ( n = 6 biologically independent samples) p < 0.01. c Representative LC3 immunoblot from FOXH1-overexpressing cells. d Quantification of the LC3II/LC3I ratio normalized to Coomassie stained immunoblots, used as loading control ( n = 6 independent experiments). e FOXH1 RT-qPCR in SAHA-treated HeLa cells (20 μM for 24 h; n = 7 biologically independent samples). f Representative immunoblot of FOXH1 overexpression in HeLa cells treated with DMSO or SAHA (20 μM for 24 h). g Quantification of f ( n = 3 independent experiments) normalized to Coomassie stained immunoblots, used as loading control. h MYC binding to the FOXH1 locus obtained from ChIP-seq datasets for U2OS cells overexpressing MYC. i Expression of the FOXH1 gene in U2OS cells with MYC overexpression, data obtained from Walz et al. j RT-qPCR of Foxh1 in tumorpheres Trp53 −/− overexpressing Myc . Values are relative to those obtained in control Trp53 −/− cells ( n = 5 biologically independent samples). k RT-qPCR of FOXH1 in U2OS cells in which MYC was silenced by shRNA. Boxes represent the mean value and bar inside the box represents median value; upper bar represents maximum of distribution; lower bar represents minimum of distribution (95% confidence level). Graphs are presented as mean ± SD. Statistical analysis was performed using the Student t -test
Article Snippet: Membranes were immunoblotted for
Techniques: Binding Assay, Quantitative RT-PCR, Western Blot, Staining, Control, Over Expression, ChIP-sequencing, Expressing, shRNA
Journal: Nature Communications
Article Title: MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat
doi: 10.1038/s41467-019-11568-0
Figure Lengend Snippet: HDACs/MYC–MiT/TFE axis in cancer and pluripotent stem cells. a Immunohistochemical analysis of MYC, TFE3, and HDAC2 in colon carcinoma samples. Regions marked by thick black arrows show that the nuclear expression of MYC and HDAC2 are common in subpopulations of neoplastic adenocarcinoma cells, especially at the invasive edges of the tumors. TFE3 appears to be more frequently localized to the cytoplasm in these same cells. Scale bar 25 μm. b MYC, TFE3, and HDAC2 expression levels in the cytoplasm and the nucleus of neoplastic cells were scored separately ( n = 6 independent tumors). c – e Protein levels of ( c ) HDAC1, HDAC2, TFEB, and MYC, ( d ) of lysosomal enzymes and lysosomal membrane components and ( e ) of autophagy effectors detected in proteomics of human fibroblasts ( n = 4 biologically independent samples) and reprogrammed hiPSCs, ( n = 7 biologically independent samples). f Representative immunoblots of hiPSCs and their parental fibroblasts probed with anti-MYC, anti-HDAC2, anti-NEU1 and anti-LAMP1 antibodies. Boxes represent the mean value and bar inside the box represents median value; upper bar represents maximum of distribution; lower bar represents minimum of distribution (95% confidence level). Graphs are shown as mean ± SD. Statistical analysis was performed using the Student t -test. ** p < 0.01, *** p < 0.001, **** p < 0.0001
Article Snippet: Membranes were immunoblotted for
Techniques: Immunohistochemical staining, Expressing, Membrane, Western Blot